<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120405</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT #2010-018703-28</org_study_id>
    <nct_id>NCT01120405</nct_id>
  </id_info>
  <brief_title>Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery</brief_title>
  <acronym>CARVASAXe</acronym>
  <official_title>Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery: A Phase III Multicenter Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Air Liquide Santé International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BIOMNIS Central laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MONITORING FORCE GROUP CROs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INFERENTIAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Air Liquide Santé International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective is to show non inferiority in cardiac safety (i.e myocardial
      necrosis-MN- assessed by positive cardiac Troponin I -cTnI- ultrasensitive assay) of a Xenon
      based general anesthesia procedure in patients with elevated cardiac risk scheduled for
      atherosclerotic vascular surgery (i.e patient with Coronary Arteries Disease risk) when
      compared to sevoflurane based general anesthesia procedure, postoperatively up to 3 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary endpoint is defined as an increase above the 99th percentile of highly sensitive
      cardiac Troponin I (cTnI) at any time during the 72 h post operatively. Time frame 3 days
      post-op;

      Key secondary endpoint(s) are routine (Local laboratory) dosage of standard cardiac Troponin
      I (cTnI) at D1 (24h) and D3 (72 h) post operatively, and also in case of any suspicion of
      Myocardial Infarction , Routine cardiac safety monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Myocardial Necrosis (MN)</measure>
    <time_frame>3 Postoperative Days</time_frame>
    <description>Myocardial Necrosis: at least 1 value of serum cardiac troponin I above the 99th percentile (measurement performed by a central laboratory using the ABBOTT-ARCHITECT technique)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Troponin I or T Above the 99th Percentile (Local Laboratories)</measure>
    <time_frame>3 Postoperative days</time_frame>
    <description>At least 1 value of serum cardiac troponin I or T above the 99th percentile (measurements performed by local laboratories using different techniques)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>3 Postoperative Days</time_frame>
    <description>Patients with Confirmed Myocardial Infarction (MI) by the Investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cerebro-Vascular Event</measure>
    <time_frame>3 postoperative days</time_frame>
    <description>Patients with Cerebro-Vascular Event in the FAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Life-Threatening Arrhythmia</measure>
    <time_frame>3 Postoperative Days</time_frame>
    <description>Patients with Life-Threatening Arrhythmia in the FAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died From Cardiac Origin</measure>
    <time_frame>3 postoperative days</time_frame>
    <description>No patient died from a cardiac cause during the 3 postoperative days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint</measure>
    <time_frame>3 postoperative days</time_frame>
    <description>Patients with at least 1 event among MN assessed by central laboratory, MI, Cerebro-Vascular event, Life-Threatening Arrhythmia and Death from Cardiac Origin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>From pre-induction to recovery of anesthesia</time_frame>
    <description>Repeated Systolic Blood Pressure measurements during the perioperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (SBP and DBP Changes)</measure>
    <time_frame>From pre-induction to Postoperative Day 3</time_frame>
    <description>Changes from baseline for Systolic and Diastolic Blood Pressure (SBP and DBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (Heart Rate Changes)</measure>
    <time_frame>From pre-induction to Postoperative Day 3</time_frame>
    <description>Changes from baseline for Heart Rate (HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chest Pain During the 3 Postoperative Days</measure>
    <time_frame>From Day 0 until Postoperative Day 3</time_frame>
    <description>Patients with Chest Pain reported at least once per day during the 3 Postoperative Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Output</measure>
    <time_frame>From Day 0 until Postoperative Day 1</time_frame>
    <description>Urine volume in milliliter (mL) during the first postoperative hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Elevated Cardiac Risk</condition>
  <condition>Coronary Arteries Disease Risk</condition>
  <arm_group>
    <arm_group_label>Xenon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon</intervention_name>
    <arm_group_label>Xenon</arm_group_label>
    <other_name>LENOXe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>sevoflurane</arm_group_label>
    <other_name>Sevo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Scheduled for atherosclerotic vascular elective surgery with presumed fast-track,

          -  Cardiac ischaemic risk supported by:

               -  History of myocardial infarction older than 1 month and/or

               -  Documented Stable angina (asymptomatic ± medical treatment) and/or

               -  History of coronary revascularisation, and/or

               -  Surgical Risk Index (&quot;Lee&quot; index) ≥ 3.

               -  Written informed consent

        Exclusion Criteria:

          -  Unstable angina within the last 30 days,

          -  Non controlled arterial Hypertension .

          -  Severe Cardiac heart Failure (NYHA IV)

          -  Severe Chronic Obstructive Pulmonary Disease

          -  Patient already randomized in another ongoing clinical trial

          -  Patient with recent myocardial infarction (M.I) (less than one month )

          -  Patient already included in a clinical trial

          -  History of hypersensitivity to study drugs( i.e Xenon, propofol, sevoflurane,
             desflurane, isoflurane)

          -  Malignant hyperthermia

          -  Documented Elevated intracranial pressure

          -  Preeclampsia or eclampsia

          -  Pregnancy and lactation

          -  Presumed uncooperativeness or legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanncik Le Manach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU PITIE SALPETRIERE, PARIS, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre CORIAT, MD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>CHU PITIE SALPETRIERE, PARIS, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit VALLET, MD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <state>Bouches du Rhône</state>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen - Pôle Anesthésie-Réanimation-SAMU, Avenue de la Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14033 Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <state>Côte d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Haut Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Ille et Vilaine</state>
        <zip>35009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Hôpital Cardiologique, Département Anesthésie-Réanimation, Bld du Président Jules Leclerc</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <state>Puy de Dôme</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <state>Val de Marne</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers, Service Anesthésie-Réanimation, 2 rue de Milétrie, BP577</name>
      <address>
        <city>Poitiers</city>
        <state>Vienne</state>
        <zip>86021 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <results_first_submitted>March 20, 2014</results_first_submitted>
  <results_first_submitted_qc>May 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xenon</keyword>
  <keyword>Cardiac safety</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Non cardiac surgery</keyword>
  <keyword>Atherosclerotic vascular surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Xenon</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xenon</title>
          <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
        </group>
        <group group_id="P2">
          <title>Sevoflurane</title>
          <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
      <group_list>
        <group group_id="B1">
          <title>Xenon</title>
          <description>0.8-1.1 Minimal Alveolar Concentration in 30% oxygen (Group A)</description>
        </group>
        <group group_id="B2">
          <title>Sevoflurane</title>
          <description>0.8-1.1 Minimal Alveolar Concentration in 30% oxygen (Group B)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="295"/>
            <count group_id="B3" value="590"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="10.3"/>
                    <measurement group_id="B2" value="71.2" spread="10.2"/>
                    <measurement group_id="B3" value="70.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Baseline Cardiac Troponin (Central Laboratory)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt; 99th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤ 99th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Myocardial Necrosis (MN)</title>
        <description>Myocardial Necrosis: at least 1 value of serum cardiac troponin I above the 99th percentile (measurement performed by a central laboratory using the ABBOTT-ARCHITECT technique)</description>
        <time_frame>3 Postoperative Days</time_frame>
        <population>Per protocol set (PPS): Randomised patients who started general anaesthesia induction and with no major protocol violations. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Necrosis (MN)</title>
          <description>Myocardial Necrosis: at least 1 value of serum cardiac troponin I above the 99th percentile (measurement performed by a central laboratory using the ABBOTT-ARCHITECT technique)</description>
          <population>Per protocol set (PPS): Randomised patients who started general anaesthesia induction and with no major protocol violations. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The percentage of patients with MN during the 3 postoperative days in the sevoflurane group and in the xenon group was expected to be 20%. The margin of non-inferiority was 10%. Thus the sample size to prove non-inferiority was 252 patients per group with α = 0.025, a power of 0.80 and the following hypotheses: H0: Px-Pc ≥ 10%; H1: Px-Pc &lt; 10%.
As it was expected that approximately 15% of patients would be non-evaluable, a total of 600 patients were included.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of xenon over sevoflurane is accepted if the upper bound of the two-sided 95% CI around the estimated difference is below the prespecified non-inferiority margin of 10%.</non_inferiority_desc>
            <p_value>0.0052</p_value>
            <method>Difference of proportion</method>
            <param_type>Difference of proportion</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.70</ci_lower_limit>
            <ci_upper_limit>7.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Troponin I or T Above the 99th Percentile (Local Laboratories)</title>
        <description>At least 1 value of serum cardiac troponin I or T above the 99th percentile (measurements performed by local laboratories using different techniques)</description>
        <time_frame>3 Postoperative days</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Troponin I or T Above the 99th Percentile (Local Laboratories)</title>
          <description>At least 1 value of serum cardiac troponin I or T above the 99th percentile (measurements performed by local laboratories using different techniques)</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="20" upper_limit="34"/>
                    <measurement group_id="O2" value="25" lower_limit="20" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7715</p_value>
            <method>Difference of proportion</method>
            <param_type>Difference of proportion</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>5.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Patients with Confirmed Myocardial Infarction (MI) by the Investigators</description>
        <time_frame>3 Postoperative Days</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Patients with Confirmed Myocardial Infarction (MI) by the Investigators</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="10" upper_limit="28"/>
                    <measurement group_id="O2" value="3" lower_limit="10" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4763</p_value>
            <method>Difference of proportion</method>
            <param_type>Difference of proportion</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cerebro-Vascular Event</title>
        <description>Patients with Cerebro-Vascular Event in the FAS</description>
        <time_frame>3 postoperative days</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cerebro-Vascular Event</title>
          <description>Patients with Cerebro-Vascular Event in the FAS</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6533</p_value>
            <method>Difference of proportion</method>
            <param_type>Difference of proportion</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.82</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Life-Threatening Arrhythmia</title>
        <description>Patients with Life-Threatening Arrhythmia in the FAS</description>
        <time_frame>3 Postoperative Days</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Life-Threatening Arrhythmia</title>
          <description>Patients with Life-Threatening Arrhythmia in the FAS</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1559</p_value>
            <method>Difference of proportion</method>
            <param_type>Difference of proportion</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died From Cardiac Origin</title>
        <description>No patient died from a cardiac cause during the 3 postoperative days.</description>
        <time_frame>3 postoperative days</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died From Cardiac Origin</title>
          <description>No patient died from a cardiac cause during the 3 postoperative days.</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint</title>
        <description>Patients with at least 1 event among MN assessed by central laboratory, MI, Cerebro-Vascular event, Life-Threatening Arrhythmia and Death from Cardiac Origin</description>
        <time_frame>3 postoperative days</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint</title>
          <description>Patients with at least 1 event among MN assessed by central laboratory, MI, Cerebro-Vascular event, Life-Threatening Arrhythmia and Death from Cardiac Origin</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="60" upper_limit="62"/>
                    <measurement group_id="O2" value="56" lower_limit="50" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6056</p_value>
            <method>Difference of proportion</method>
            <param_type>Difference of proportion</param_type>
            <param_value>1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.74</ci_lower_limit>
            <ci_upper_limit>8.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP)</title>
        <description>Repeated Systolic Blood Pressure measurements during the perioperative period</description>
        <time_frame>From pre-induction to recovery of anesthesia</time_frame>
        <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <description>Repeated Systolic Blood Pressure measurements during the perioperative period</description>
          <population>Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.1" spread="21.6"/>
                    <measurement group_id="O2" value="147.3" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum SBP-Induction Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" spread="21.3"/>
                    <measurement group_id="O2" value="90.3" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum SBP-Maintenance Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" spread="17.8"/>
                    <measurement group_id="O2" value="83.8" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum SBP- Awakening Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.8" spread="25.1"/>
                    <measurement group_id="O2" value="117.6" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum SBP-Induction Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.0" spread="26.9"/>
                    <measurement group_id="O2" value="153.6" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum SBP- Maintenance Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.8" spread="28.0"/>
                    <measurement group_id="O2" value="144.6" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum SBP-Awakening Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.6" spread="29.1"/>
                    <measurement group_id="O2" value="153.4" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (SBP and DBP Changes)</title>
        <description>Changes from baseline for Systolic and Diastolic Blood Pressure (SBP and DBP)</description>
        <time_frame>From pre-induction to Postoperative Day 3</time_frame>
        <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (SBP and DBP Changes)</title>
          <description>Changes from baseline for Systolic and Diastolic Blood Pressure (SBP and DBP)</description>
          <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="25.4"/>
                    <measurement group_id="O2" value="-14.2" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP-Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="26.6"/>
                    <measurement group_id="O2" value="-10.7" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP-Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="24.7"/>
                    <measurement group_id="O2" value="-12.2" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="14.91"/>
                    <measurement group_id="O2" value="-6.15" spread="15.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP- Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" spread="14.53"/>
                    <measurement group_id="O2" value="-1.46" spread="13.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP-Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.73" spread="14.05"/>
                    <measurement group_id="O2" value="-2.61" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (Heart Rate Changes)</title>
        <description>Changes from baseline for Heart Rate (HR)</description>
        <time_frame>From pre-induction to Postoperative Day 3</time_frame>
        <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimal Alveolar Concentration in 30% oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimal Alveolar Concentration in 30% oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Heart Rate Changes)</title>
          <description>Changes from baseline for Heart Rate (HR)</description>
          <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="12.03"/>
                    <measurement group_id="O2" value="6.35" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR-Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" spread="13.64"/>
                    <measurement group_id="O2" value="9.85" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR-Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" spread="11.72"/>
                    <measurement group_id="O2" value="8.90" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chest Pain During the 3 Postoperative Days</title>
        <description>Patients with Chest Pain reported at least once per day during the 3 Postoperative Days</description>
        <time_frame>From Day 0 until Postoperative Day 3</time_frame>
        <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chest Pain During the 3 Postoperative Days</title>
          <description>Patients with Chest Pain reported at least once per day during the 3 Postoperative Days</description>
          <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Output</title>
        <description>Urine volume in milliliter (mL) during the first postoperative hours</description>
        <time_frame>From Day 0 until Postoperative Day 1</time_frame>
        <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenon</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane</title>
            <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Output</title>
          <description>Urine volume in milliliter (mL) during the first postoperative hours</description>
          <population>Treated set (TS): Randomised patients who received the study medication. Patients were assigned to the treatment groups as treated, i.e. the treatment groups were based on the treatment actually received.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279.0" spread="723.1"/>
                    <measurement group_id="O2" value="1324.4" spread="631.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events observed after the start of study drug administration and during postoperative 3-day period</time_frame>
      <desc>Participants at risks are the patients from the Treated Set, ie randomised patients who received the study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Xenon</title>
          <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group A)</description>
        </group>
        <group group_id="E2">
          <title>Sevoflurane</title>
          <description>0.8-1.1 Minimum Alveolar Concentration in 30 % oxygen (Group B)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Subendocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallblader Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Procedural Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Operative Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Shunt Trombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Procedural Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Procedural Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Air Liquide Sante International may delay publication or disclosure for a term not exceeding eighteen (18) months with effect from the request in the event that Air Liquide Sante International wishes to seek protection of the results of the Trial by industrial property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yannick LE MANACH, MD, PhD</name_or_title>
      <organization>Population Health Research Institute - Mc Master University, Hamilton CANADA</organization>
      <phone>0012892606840</phone>
      <email>Yannick.Lemanach@phri.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

